Moderna settles all patent litigation with Arbutus/Genevant for $950M upfront, up to $1.3B contingent

Moderna, Inc.

Moderna to pay $950M noncontingent lump sum by July 8, 2026 to resolve worldwide patent litigation over Spikevax and mRESVIA.
Additional $1.3B contingent payment due if Moderna loses appeal on Section 1498 government contractor defense at Federal Circuit.
Settlement includes fully paid-up, royalty-free license for Moderna's infectious disease vaccines using SM-102 LNP (Spikevax, mNEXSPIKE, mRESVIA, future pipeline).
Moderna may appeal Section 1498 issue; if partially successful, prorated amount of $1.3B may be due; if fully successful, no further payment.
Agreement provides mutual releases and dismissals of all pending claims in U.S. and international litigation.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Moderna, Inc. entered into Settlement Agreement with Arbutus Biopharma Corporation and Genevant Sciences GmbH valued at $950 million noncontingent lump sum payment (effective 2026-03-03).

Action: entry
Agreement: settlement
Counterparty: Arbutus Biopharma Corporation and Genevant Sciences GmbH
Value: $950 million noncontingent lump sum payment
Effective: 2026-03-03

Exact text from the filing

On March 3, 2026 (the “Effective Date”), Moderna, Inc. (the “Company”) and ModernaTX, Inc. (together with the Company, “Moderna”) and Arbutus Biopharma Corporation (“Arbutus”), Genevant Sciences GmbH (“Genevant” and, together with Arbutus, “Arbutus/Genevant”), and, solely for certain purposes, Genevant Sciences Ltd., entered into a settlement agreement (the “Settlement Agreement”) to resolve all patent infringement litigation between Moderna and Arbutus/Genevant pending in the U.S. and internationally (the “Litigation”).

View on SEC.gov

Browse all material agreements →

Moderna, Inc. filing history →

Source: SEC EDGAR

accession 0001682852-26-000047

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.